Signal active
Organization
Contact Information
Overview
ArsenalBio is building a programmable cell therapy company to create highly effective and accessible immune cell therapies to impact outcomes for a much broader number of patients, initially those with cancer. Founded in 2019, ArsenalBio is focused on integrating technologies such as CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and machine learning to advance a new paradigm to discover and develop immune cell therapies. With its programmable and computationally driven approach, ArsenalBio aspires to evolve critical metrics of success for immune cell therapies, including enhanced and broader efficacy, increased patient safety, reduced provider costs, and expanded market access.
About
Cloud Computing, Biotechnology, Life Science, Medical
2019
251-500
Headquarters locations
United States, North America
Social
N/A
Profile Resume
ArsenalBio headquartered in United States, North America, operates in the Cloud Computing, Biotechnology, Life Science, Medical sector. The company focuses on Cloud Computing and has secured $9.8B in funding across 32 round(s). With a team of 251-500 employees, ArsenalBio is actively contributing to advancements in Cloud Computing. Their latest funding round, Series B - ArsenalBio, raised $220.8M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
2
14
0
$305.8M
Details
2
ArsenalBio has raised a total of $305.8M in funding over 2 rounds.
Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
---|---|---|---|---|
2019 | Early Stage Venture | 85.0M | ||
2022 | Early Stage Venture | 220.8M |
Investors
ArsenalBio is funded by 22 investors.
Investor Name | Lead Investor | Funding Round | Partners |
---|---|---|---|
Euclidean Capital | - | FUNDING ROUND - Euclidean Capital | 220.8M |
Sixth Street | - | FUNDING ROUND - Sixth Street | 220.8M |
ArsenalBio | - | FUNDING ROUND - ArsenalBio | 220.8M |
Triatomic Capital | - | FUNDING ROUND - Triatomic Capital | 220.8M |
Recent Activity
There is no recent news or activity for this profile.